The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Commentary|Videos|May 15, 2025
Clinical Trial Diversity, Equity, and Inclusion and the Path Forward
Author(s)Fatima Karzai, MD
Fatima Karzai, MD, discusses clinical trial diversity, equity, and inclusion and the path forward.
Advertisement
Fatima Karzai, MD, discusses clinical trial diversity, equity, and inclusion and the path forward.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Advertisement
Advertisement
Trending on OncLive
1
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5